Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)

@article{Segal2002TreatmentOO,
  title={Treatment of obstetric hemorrhage with recombinant activated factor VII (rFVIIa)},
  author={Shmuel Segal and Iftah Y Shemesh and Rosalyn Blumenthal and Boris Yoffe and Neri Laufer and Yossef Ezra and Irene Levy and Moshe Mazor and Uriel Martinowitz},
  journal={Archives of Gynecology and Obstetrics},
  year={2002},
  volume={268},
  pages={266-267}
}
Recombinant activated factor VII (rFVIIa, NovoSeven®) was used in three patients with massive obstetric hemorrhage due to placenta previa accreta, rupture of the uterus and pre-eclampsia with HELLP. Administration of the drug markedly decreased the bleeding and enabled control of the hemorrhage. rFVIIa seems to be an adjunctive hemostatic measure for the treatment of severe obstetric hemorrhage. 

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

[Anesthetic management of severe or worsening postpartum hemorrhage].

Journal de gynecologie, obstetrique et biologie de la reproduction • 2014
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-6 of 6 references

New approach for the management of coagulation at the site of injury by recombinant activated factor VII (rVIIa)

U Martinowitz, J Luboshitz, A Lubetsky, G Kenet
Blood • 2001
View 5 Excerpts
Highly Influenced

Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII

F Moscardo, F Perez, +6 authors MA Sanz
Br J Haematol • 2001
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…